Simvastatin

This classification denotes a hmg-coa reductase inhibitor with the molecular formula C25H38O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AGG2FN16EV, chemically known as 2,2-dimethylbutyric acid, 8-ester with (4r,6r)-6-(2-((1s,2s,6r,8s,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2h-pyran-2-one but generally known as simvastatin, which bears US NIH Compound Identifier 54454. European Medicines Agency schedules Simvastatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10529MIG. The term SIMVASTATIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, No. 3, 1988, List 28). World Health Organization schedules simvastatin in its Anatomical Therapeutic Chemical (ATC) Classification. SIMVASTATIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, SIMVASTATIN remains the US FDA Preferred Term for this commodity. Simvastatin bears US NLM identifiers UMLS ID C0074554 and NCI Concept Code C29454. SMILES: O(C1C2C(C(C=CC2=CC(C1)C)C)CCC1OC(=O)CC(O)C1)C(=O)C(CC)(C)C.